Express News | Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships
Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $470
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
Akero Surges After Report on Plans for Potential Sale
Is Madrigal Pharmaceuticals (NASDAQ:MDGL) Using Too Much Debt?
Paulson & Co Takes New Stake in Honeywell in Q1
Promising Phase III Trial Results Support Buy Rating for Madrigal Pharmaceuticals
Citi Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $456
Uncertainties and Data Gaps Lead to Sell Rating for Madrigal Pharmaceuticals' Rezdiffra
Express News | Madrigal Pharmaceuticals: 65% Of Patients With Clinically Significant Portal Hypertension at Baseline Moved Into Lower Risk Categories by Year Two
Express News | Madrigal Pharmaceuticals Inc - Rezdiffra Well-Tolerated With Low Discontinuation Rate
Express News | Madrigal Pharmaceuticals Inc - Patients Achieved 6.7 Kpa Reduction in Liver Stiffness
Express News | Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (Resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients With Compensated Mash Cirrhosis
Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson's Stocks With Huge Upside Potential
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Maintains Target Price $248
Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Madrigal Pharmaceuticals Analyst Ratings
Express News | Madrigal Pharmaceuticals Inc : UBS Raises Target Price to $458 From $441